ONCOPEPTIDES AB [CBOE] news, videos and press releases - Page 3
For more news please use our advanced search feature.
ONCOPEPTIDES AB [CBOE] - More news...
ONCOPEPTIDES AB [CBOE] - More news...
- Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D
- Oncopeptides' CFO Anders Martin-Löf will leave the company
- Oncopeptides presents phase 3 OCEAN study results at the IMW meeting
- Invitation to webcast for presentation of OCEAN data presented at IMW
- Invitation to webcast for presentation of OCEAN data presented at IMW
- Regulatory update from US Food and Drug Administration
- Regulatory update from US Food and Drug Administration
- Oncopeptides presents new data from OCEAN and PORT study - abstracts online
- Oncopeptides presents new data from OCEAN and PORT study - abstracts online
- Oncopeptides publishes report for Q2 2021
- Oncopeptides publishes report for Q2 2021
- Oncopeptides' PEPAXTO® Receives a Permanent J-Code, Clarifying Reimbursement Processes in Hospital Outpatient and Physician Office Settings of Care
- Invitation to presentation of the Q2 2021 results
- Invitation to presentation of the Q2 2021 results
- Regulatory update from US Food and Drug Administration
- Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS - Overall Survival data lead to partial clinical hold
- Number of shares and votes in Oncopeptides
- Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
- Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
- Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021
- Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021
- Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma
- Oncopeptides AB: Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma
- Oncopeptides AB: Invitation to presentation of the Q1 2021 results
- Oncopeptides AB: Invitation to presentation of the Q1 2021 results
- Oncopeptides announces three abstracts accepted by the 2021 American Society of Clinical Oncology
- Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology
- Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch
- Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting
- Oncopeptides completes patient enrollment in phase 2 PORT study